North American Opiate Medication Initiative (NAOMI Study)

North American Opiate Medication Initiative (NAOMI Study)

October 16, 2008 11:30 ET

NAOMI Study: Media Advisory; Researchers to Present Results From North America's First Clinical Trial of Medically Prescribed Heroin Therapy

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 16, 2008) - Researchers from the North American Opiate Medication Initiative (NAOMI Study) will host a news conference at St. Paul's Hospital on Friday, October 17 to share study data.

What: Researchers will present final results of the primary outcomes data from the NAOMI Study - a three-year randomized controlled clinical trial comparing prescribed heroin to optimized methadone for people with chronic heroin addiction. NAOMI researchers will be available for questions and interviews following the news conference.

Who: Mrs. Dianne Doyle, President & CEO, Providence Health Care
(event emcee)
Dr. Martin Schechter, Principal Investigator, Centre for Health
Evaluation and Outcome Sciences, Professor and Director, University
of British Columbia School of Population and Public Health, Canada
Research Chair in HIV/AIDS and Urban Population Health

When: Friday, October 17, 2008 at 9:45 a.m.

Where: Gourlay Conference Room
The James Hogg iCapture Centre
St. Paul's Hospital (Main floor, Burrard Building)
1081 Burrard Street, Vancouver, B.C.

Media are asked to meet by 9:30 a.m. at Burrard entrance Information
Desk and will be escorted to the news conference by Providence
Health Care Communications representatives.

About the NAOMI Study

The NAOMI study tested whether heroin-assisted therapy or optimized methadone therapy is better for improving the health and quality of life of long-time opiate users. Eligible participants were randomly assigned to receive a 12-15-month course of medically prescribed injection opioids (heroin or hydromorphone) or oral methadone therapies. Following a steady recruitment of volunteers who met the study's rigorous inclusion criteria, NAOMI fully enrolled 251 participants (192 in Vancouver and 59 in Montreal) by March 2007. The treatment phase of the study was completed in June 2008. Researchers will continue to gather and analyze data until NAOMI's expected closure in mid-2009. Funded by the Canadian Institutes of Health Research, and approved by Health Canada, NAOMI enrolled and treated participants in Vancouver and Montreal since 2005.

For further information, please visit:

Funding provided by the Canadian Institutes of Health Research.

Contact Information

  • NAOMI Study
    Julie Schneiderman, Canadian HIV Trials Network
    Programme Head, Communications & Information
    (604) 806-8380
    Providence Health Care
    Alex Vondette
    Communications Specialist
    (604) 806-9857